The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19

Pharmacodynamic evidence that vilobelimab efficiently inhibits C5a in patients with severe COVID-19.

Publication · 2024-11-06

More detail is on the way.

Full content is being migrated into the new site. Reach out and a senior contact will send you a copy directly.

Related services

Resource library

All white papers, case studies, publications and blogs.

Publications

Peer-reviewed and journal articles.

Contact us

Talk to a senior contact about the work behind this.